CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event
16 juin 2021 06h30 HE
|
CENTOGENE GmbH
Recorded revenues of €65.0 million in Q1 2021, driven by revenues from COVID-19 testing, up over 400% compared to €12.1 million in Q1 2020Achieved positive adjusted EBITDA, driven by COVID-19 testing...
CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021
09 juin 2021 16h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 09, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Announces Virtual Investor Event
07 juin 2021 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia
02 juin 2021 06h31 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 02, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution
01 juin 2021 06h30 HE
|
CENTOGENE GmbH
World leader and trusted partner in rare diseases releases enhanced Whole Exome Sequencing (WES) solution to improve diagnosis in complex and unsolved patient casesNEW CentoXome® provides...
CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer
26 mai 2021 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 26, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals
18 mai 2021 06h30 HE
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENE Extends Global Parkinson’s Disease Study
10 mai 2021 06h30 HE
|
CENTOGENE GmbH
Providing patients with genetic testing designed to accelerate the diagnosis and personalized treatment of Parkinson’s disease (PD) The Rostock International Parkinson's Disease (ROPAD) Study aims to...
New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases
06 mai 2021 06h30 HE
|
CENTOGENE GmbH
Database has grown to more than 465,000 analyzed patients, with more than 225,000 being linked to HPO termsRelease includes increase of almost 19 million to over 31 million unique variants New...
CENTOGENE Discovers Six New Rare Diseases by Leveraging the Strength of Its Bio/Databank
05 mai 2021 06h30 HE
|
CENTOGENE GmbH
More than half of patients with genetic diseases remain undiagnosed, even after performing Exome and Genome SequencingBy performing deep genetic analyses and Bio/Databank mining, CENTOGENE discovers...